Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma

Abstract Background This retrospective analysis of data from clinical trials in metastatic urothelial carcinoma (mUC) was conducted to determine baseline patient characteristics associated with long-term survival (LTS) following treatment with immune checkpoint inhibitors. Methods Data for this anal...

Full description

Bibliographic Details
Main Authors: Marie Alt, Carlos Stecca, Yian Lin, Gbenga Kazeem, Erik T. Goluboff, Srikala S. Sridhar
Format: Article
Language:English
Published: BMC 2023-09-01
Series:BMC Cancer
Subjects:
Durvalumab
Immune checkpoint inhibitor
Long-term survival
Multivariable analysis
Predictive factors
Univariable analysis
Online Access:https://doi.org/10.1186/s12885-023-11380-6

Internet

https://doi.org/10.1186/s12885-023-11380-6

Similar Items